Hepatitis B News and Research

Latest Hepatitis B News and Research

HFA urges American Red Cross to end current labor issues over blood supply

The Hemophilia Federation of America (HFA) expresses its concern regarding the ongoing labor issues involving the Teamsters Local 929 and the American Red Cross of Pennsylvania /New Jersey.

15 Dec 2009

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.

11 Dec 2009

Speaker Pelosi lauds lift of ban on federal funding for syringe exchange initiatives

Speaker Nancy Pelosi issued the following statement today applauding the inclusion of language in the fiscal year 2010 Consolidated Appropriations Act lifting the ban on federal funding for syringe exchange initiatives to prevent the spread of HIV. The omnibus bill passed the House this afternoon by a vote of 221 to 202.

11 Dec 2009

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

Travelers may risk both health and travel insurance coverage by not getting vaccinated

With tens of thousands of people set to travel abroad over the Christmas period, AA Travel Insurance are today urging travellers to be properly vaccinated before travelling.

8 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security.

5 Dec 2009

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

Following a long and difficult negotiations process, public health nurses with the Sudbury & District Public Health Unit have reached a tentative settlement with their employer.

4 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

In a New Republic/NPR opinion piece, Harold Pollack, an associate professor at the University of Chicago School of Social Service Administration, looks at the media's coverage of World AIDS Day. "Almost six thousand people died of AIDS [Tuesday]. ... That it happened to be World AIDS Day was almost incidental. AIDS was certainly incidental to much of the mainstream media.

4 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

Hepatitis B News and Research

Latest Hepatitis B News and Research

HFA urges American Red Cross to end current labor issues over blood supply

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

Speaker Pelosi lauds lift of ban on federal funding for syringe exchange initiatives

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Travelers may risk both health and travel insurance coverage by not getting vaccinated

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

New Center for Digestive Care to care for all aspects of digestive disease

New SPC3649 drug found effective in treating HCV infections

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in